McAllen's adult obesity and uninsured rates, the local teaser-month pricing decoded, Hidalgo County's worsening shortage designations, and Texas coverage rules, every figure sourced.
44.3% of adults inside McAllen city limits have obesity, per the CDC's PLACES place-level estimates (2024 release, 2022 survey data) 1. That is among the highest place-level rates the CDC publishes for any sizable US city. Texas as a whole is 35.6% in the CDC's 2024 BRFSS estimates 2; the two figures come from different survey years, so read the gap as a direction rather than a decimal.
The second number decides how care actually gets paid for here: 17.8% of McAllen residents have no health insurance, the highest rate of any city we have built a page for, nearly one in five people 5. Texas Medicaid categorically excludes anti-obesity medications 8. In a market like that the cash price is not a fallback, it is the front door, so this page leads with it.
HRSA's shortage-area data shows six simultaneous low-income primary-care HPSA designations covering Hidalgo County: the McAllen Service Area, designated March 2026, covering 68,993 people at a 3,495-to-1 population-to-provider ratio, plus Mission, Edinburg, Pharr/San Juan/Alamo, East, and Northwest 7. Several of those designations were made only between late 2025 and mid-2026, which means the federal record describes a shortage that is actively being extended, not a historical artifact.
Specialist capacity is thin against a metro of 914,820 people 4. RGV Endocrine Center's physician is triple-boarded in internal medicine, endocrinology, and obesity medicine, which is real credentialing, but it is boutique scale for the population, and the route in is an insurance-based specialist appointment 10. For an uninsured resident at a 17.8% uninsured rate 5 and a median household income of $60,907 6, that door is often closed before it opens.
This is where telehealth is the practical answer. With Astra, a licensed Texas provider reviews your intake usually within 24 hours, medication ships overnight in discreet packaging, no clinic visit is required at any point, you can message your care team throughout treatment, and you are only charged if a provider prescribes.
Texas Medicaid does not cover GLP-1s prescribed for weight loss. The exclusion is categorical rather than case-by-case: anti-obesity medications sit outside the benefit, and a GLP-1 reaches the pharmacy benefit only through a diabetes indication 8. Commercial coverage varies by employer plan, so the useful step is to look up Wegovy or Zepbound on your plan's formulary and check whether weight-management indications are excluded before you assume either answer.
The full Texas picture, including prescribing statutes and compounding rules, is on the Texas GLP-1 hub 9.
Astra's provider group and partner pharmacies are licensed to serve patients across Texas, the Rio Grande Valley included, so McAllen, Edinburg, Mission, and Pharr are inside our service area on the same terms as the rest of the state. A Spanish version of this page is available at Leer en español.
Astra treats patients in Texas through state-licensed physicians.
Because the advertised number is usually an introductory month. Medi-Weightloss McAllen advertises $99 for the first month of compounded semaglutide and $199 for the first month of tirzepatide, with plans starting at $199 per month afterward plus a one-time $199 new-patient visit fee. Telehealth programs advertising a price "starting at" a figure quote a floor, and membership can be billed separately from medication. Astra charges the same amount in month one as in month twelve.
On the published figures, yes. After the introductory month, the advertised local plans run $199 or more per month plus a one-time $199 enrollment fee, which works out to roughly $2,487 in a first year on the semaglutide numbers. Astra's compounded semaglutide is $68 per month on the 12-month plan, with no enrollment fee. That is a national price rather than a McAllen deal, and it is identical at every dose.
Not for weight loss. Texas Medicaid categorically excludes anti-obesity medications, so a GLP-1 reaches the benefit only through a diabetes indication. Commercial plans vary and are worth checking on your own formulary. The full state detail is on our Texas GLP-1 hub at /glp-1/texas/.
Possibly, but only within federal 503A conditions. Since FDA declared the brand-name shortages resolved, a state-licensed US compounding pharmacy generally may not compound what amounts to a copy of the approved product, and a patient-specific compounded prescription requires a prescriber-documented clinical reason that the approved product does not meet your needs. That determination is made by a licensed provider, and availability is not guaranteed. The full state rules are on our Texas GLP-1 hub at /glp-1/texas/.
No. Texas law lets a licensed provider establish the practitioner-patient relationship and prescribe non-controlled medications by telemedicine without a prior in-person exam (Occupations Code Chapter 111). The statute and its conditions are summarized in the telehealth section of /glp-1/texas/.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.